JPWO2023133394A5 - - Google Patents

Info

Publication number
JPWO2023133394A5
JPWO2023133394A5 JP2024540715A JP2024540715A JPWO2023133394A5 JP WO2023133394 A5 JPWO2023133394 A5 JP WO2023133394A5 JP 2024540715 A JP2024540715 A JP 2024540715A JP 2024540715 A JP2024540715 A JP 2024540715A JP WO2023133394 A5 JPWO2023133394 A5 JP WO2023133394A5
Authority
JP
Japan
Prior art keywords
seq
cancer
amino acid
acid sequence
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024540715A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025504363A (ja
JP2025504363A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/060074 external-priority patent/WO2023133394A1/en
Publication of JP2025504363A publication Critical patent/JP2025504363A/ja
Publication of JPWO2023133394A5 publication Critical patent/JPWO2023133394A5/ja
Publication of JP2025504363A5 publication Critical patent/JP2025504363A5/ja
Pending legal-status Critical Current

Links

JP2024540715A 2022-01-05 2023-01-04 γδT細胞結合ポリペプチド及びその使用 Pending JP2025504363A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263296774P 2022-01-05 2022-01-05
US63/296,774 2022-01-05
US202263417926P 2022-10-20 2022-10-20
US63/417,926 2022-10-20
PCT/US2023/060074 WO2023133394A1 (en) 2022-01-05 2023-01-04 Gamma delta t-cell-binding polypeptides and uses thereof

Publications (3)

Publication Number Publication Date
JP2025504363A JP2025504363A (ja) 2025-02-12
JPWO2023133394A5 true JPWO2023133394A5 (https=) 2025-12-26
JP2025504363A5 JP2025504363A5 (https=) 2025-12-26

Family

ID=85199216

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024540715A Pending JP2025504363A (ja) 2022-01-05 2023-01-04 γδT細胞結合ポリペプチド及びその使用

Country Status (11)

Country Link
US (1) US20250066477A1 (https=)
EP (1) EP4460521A1 (https=)
JP (1) JP2025504363A (https=)
KR (1) KR20240130130A (https=)
CN (1) CN119213028A (https=)
AU (1) AU2023205911A1 (https=)
CA (1) CA3242658A1 (https=)
IL (1) IL314073A (https=)
MX (1) MX2024008389A (https=)
TW (1) TW202334233A (https=)
WO (1) WO2023133394A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025144974A1 (en) * 2023-12-29 2025-07-03 Absci Corporation Half-life extending fc domain variants and uses thereof
WO2025140683A1 (zh) * 2023-12-29 2025-07-03 北京鼎成肽源生物技术有限公司 表达趋化因子10和白介素15的工程化免疫细胞
WO2026006719A1 (en) * 2024-06-28 2026-01-02 IN8bio, Inc. Multifunctional molecules and methods of treatment

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
PT1678314E (pt) 2003-10-22 2012-11-27 Keck Graduate Inst Métodos de síntese de polipéptidos heteromultiméricos em levedura utilizando uma estratégia de conjugação haplóide
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
EP3129404B1 (en) * 2014-04-10 2026-01-28 LAVA Therapeutics N.V. Immunoglobulins binding human vgamma9vdelta2 t cell receptors
GB201707048D0 (en) * 2017-05-03 2017-06-14 King S College London Expansion of gamma delta cells, compositions, and methods of use thereof
EP3864045A2 (en) * 2018-10-11 2021-08-18 Inhibrx, Inc. Dll3 single domain antibodies and therapeutic compositions thereof
CN113993893A (zh) * 2019-02-01 2022-01-28 拉法医疗有限公司 新cd40结合抗体
KR20220004751A (ko) * 2019-05-04 2022-01-11 인히브릭스, 인크. CLEC12a 결합 폴리펩타이드 및 이의 용도
JP2023504185A (ja) * 2019-12-03 2023-02-01 アディセット バイオ, インコーポレイテッド γδT細胞集団を多価薬剤で増殖させるための方法及びその組成物
WO2021176373A1 (en) * 2020-03-03 2021-09-10 Janssen Biotech, Inc. ꝩδ T CELLS AND USES THEREOF

Similar Documents

Publication Publication Date Title
JPWO2021155071A5 (https=)
JP2020536549A5 (https=)
JP2021520812A5 (https=)
JP2019513347A5 (https=)
KR102853978B1 (ko) 제3 신호 수용체를 포함하는 키메릭 항원 수용체 및 이의 용도
JP2021525524A5 (https=)
JP2018527008A5 (https=)
RU2018128462A (ru) Модифицированные клетки для иммунотерапии
RU2020142965A (ru) Иммуноглобулин с тандемным расположением fab-фрагментов и его применение
JP2015527070A5 (https=)
IL319102A (en) Guidance and navigation control proteins and method for producing and using them
JP2025078629A5 (https=)
CN104592392B (zh) 一种双特异性抗体EpCAM×CD3的构建及应用
JP2017513818A5 (https=)
JP2017506215A5 (https=)
JPWO2020135201A5 (https=)
RU2018106452A (ru) Поливалетные и полиспецифичные gitr-связывающие слитые белки
CN109153725A (zh) 一种多功能蛋白质
CN104592391A (zh) 一种双特异性抗体EpCAM×CD3的构建及应用
JPWO2020146221A5 (https=)
CN115698088A (zh) 免疫细胞衔接器多特异性结合蛋白及其制备和应用
CN113490690A (zh) 异源二聚体融合蛋白
Li et al. Nanobodies and their derivatives: pioneering the future of cancer immunotherapy
CN119213028A (zh) 结合γδ T细胞的多肽及其用途
JPWO2023004304A5 (https=)